国药一致(000028) - 2025 Q1 - 季度财报

Financial Performance - In Q1 2025, the company reported revenue of CNY 18.29 billion, a decrease of 4.17% compared to CNY 19.09 billion in the same period last year[5]. - Net profit attributable to shareholders was CNY 327.99 million, down 15.63% from CNY 388.77 million year-on-year, with basic earnings per share decreasing by 15.71% to CNY 0.59[5]. - The distribution segment generated revenue of CNY 13.59 billion, a decline of 2.61%, while net profit was CNY 23.10 million, down 3.75% year-on-year[5]. - The retail segment, represented by Guoda Pharmacy, achieved revenue of CNY 4.98 billion, a decrease of 7.49%, with net profit plummeting 94.28% to CNY 0.04 million[5]. - The net profit for the current period is CNY 347,677,306.80, a decrease of 22.1% compared to CNY 446,123,063.02 in the previous period[21]. - The total profit for the current period is CNY 438,326,864.61, down from CNY 550,249,302.13, reflecting a decline of 20.3%[21]. - The operating profit for the current period is CNY 439,138,215.70, compared to CNY 544,001,136.48 in the previous period, indicating a decrease of 19.3%[21]. - The company reported a decrease in sales revenue from CNY 16,287,280,704.30 to CNY 15,787,668,453.64, a decline of 3.1%[22]. Cash Flow and Assets - The company experienced a significant increase in cash flow from operating activities, reporting a net cash outflow of CNY 1.82 billion, compared to a net outflow of CNY 634.15 million in the previous year, marking a 186.57% decline[5]. - Cash flow from operating activities decreased by 118,312.42 million yuan, a decline of 186.57% due to increased payable notes and delayed receivables[12]. - Net cash flow from investment activities decreased by 2,047.98 million yuan, a drop of 82.44%, primarily due to reduced returns from investment projects[12]. - Cash flow from financing activities decreased by 33,042.73 million yuan, a reduction of 33.32%, mainly attributed to timing differences in factoring business[12]. - Total cash and cash equivalents decreased by 121,806.13 million yuan, a decline of 214.79%, influenced by increased payable notes and decreased sales scale[12]. - Cash and cash equivalents at the end of the period amount to CNY 5,338,493,281.93, slightly up from CNY 5,268,204,527.14 in the previous period[23]. - Current assets totaled ¥40,139,860,703.30, up from ¥37,576,395,698.77, representing an increase of 6.77%[18]. - Non-current assets decreased slightly to ¥9,883,181,465.79 from ¥9,979,464,716.45, a decline of 0.97%[18]. - Total liabilities increased to ¥28,921,099,065.70 from ¥26,800,461,097.40, marking an increase of 7.87%[19]. - Accounts receivable increased to ¥23,588,402,403.91 from ¥19,376,751,928.72, reflecting an increase of 21.43%[18]. - Inventory increased to ¥8,021,262,862.14 from ¥7,406,159,009.11, an increase of 8.31%[18]. - Long-term equity investments rose to ¥3,045,046,646.19 from ¥2,944,833,760.49, an increase of 3.41%[18]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 40,428[14]. - The largest shareholder, China National Pharmaceutical Group Corporation, holds 56.06% of shares, totaling 311,999,988 shares[15]. - The second-largest shareholder, National Social Security Fund 413 Portfolio, holds 1.36% of shares, totaling 7,560,013 shares[15]. Strategic Focus - The company is focusing on enhancing operational management in the distribution business and improving efficiency in the retail segment through dynamic management of loss-making stores[6]. - The company aims to strengthen its core business and develop a standardized management system to foster sustainable growth amidst a challenging market environment[6]. Other Financial Metrics - Basic and diluted earnings per share are both CNY 0.59, down from CNY 0.70 in the previous period[21]. - The total cash inflow from financing activities is CNY 661,184,385.13, compared to CNY 991,611,668.12 in the previous period, a decrease of 33.3%[23]. - The company incurred credit impairment losses of CNY -63,856,766.00, compared to CNY -40,849,138.51 in the previous period, indicating an increase in losses[21]. - The company has not yet audited the first quarter report for 2025[25].